Global Shigella Infections (Shigellosis) Pipeline Report 2016 - Review of Anacor Pharma, GSK, Microbiotix, Protein Potential and Visterra and Their Drug Profiles - Research and Markets

Tags:  

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Shigella Infections (Shigellosis) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects.

---

---

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

For more information visit http://www.researchandmarkets.com/research/wk5pk3/shigella

Contacts

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: Infectious Diseases Drugs

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: Infectious Diseases Drugs